1. Home
  2. LVRO vs OMER Comparison

LVRO vs OMER Comparison

Compare LVRO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lavoro Limited

LVRO

Lavoro Limited

HOLD

Current Price

$0.64

Market Cap

112.6M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.21

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LVRO
OMER
Founded
2017
1994
Country
Brazil
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.6M
628.9M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
LVRO
OMER
Price
$0.64
$9.21
Analyst Decision
Sell
Strong Buy
Analyst Count
3
5
Target Price
$1.88
$27.50
AVG Volume (30 Days)
14.6K
1.5M
Earning Date
02-02-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,667,345,189.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$11.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$2.95
52 Week High
$5.60
$13.60

Technical Indicators

Market Signals
Indicator
LVRO
OMER
Relative Strength Index (RSI) 26.21 48.80
Support Level $0.60 $8.27
Resistance Level $0.69 $11.71
Average True Range (ATR) 0.11 0.73
MACD -0.00 -0.32
Stochastic Oscillator 3.31 25.18

Price Performance

Historical Comparison
LVRO
OMER

About LVRO Lavoro Limited

Lavoro Ltd operates in the agricultural inputs retail market, with operations spread across Brazil and Colombia, and an emergent agricultural input trading company in Uruguay. The reportable segments of the company include the Brazil Ag Retail, which comprises companies dedicated to the distribution of agricultural inputs such as crop protection, seeds, fertilizers and specialty products, in Brazil; Latam Ag Retail, which includes companies dedicated to the distribution of agricultural inputs outside Brazil (predominantly in Colombia); and the Crop Care. A substantial part of the company's overall revenue is generated from its Brazil Ag Retail segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: